-+ 0.00%
-+ 0.00%
-+ 0.00%

BriaCell Secures Prime Spotlight at Major 2026 Cancer Conference to Reveal 'Next-Gen' Personalized Immunotherapy Progress

Benzinga·03/10/2026 11:36:51
Listen to the news

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that four abstracts have been accepted for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place from April 17th – 22nd at San Diego Convention Center, San Diego, CA.

The accepted abstracts highlight research related to BriaCell's cellular immunotherapy platform, including the Company's ongoing pivotal Phase 3 study of Bria-IMTᵀᴹ   in combination with an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612) and research supporting Bria-OTS+ᵀᴹ, BriaCell's next-generation personalized off-the-shelf immunotherapy program.

Poster titles and presentation details will become available on March 17, 2026 at 4:30 PM ET, when the abstracts will be published in the online Proceedings of AACR.